Clinical trial · no report yet · Phase 3
ICTAN
Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR Mutation
- NCT01996098 ↗
- Terminated
- Sun Yat-sen University
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 8 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A Multicenter, Randomized, Phase III Trial of Chemotherapy Followed by 6-month or 12-month Icotinib Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA Non-small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation
- Phase
- Phase 3
- Status
- Terminated
- Conditions
- Lung Cancer
- Interventions
- 6-month Icotinib; 12-month icotinib
- Arms
- 6-month icotinib · Experimental
- 12-month icotinib · Experimental
- Chemotherapy alone · No intervention
- Enrollment
- 251
- Primary outcomes
- Disease-Free Survival
- Sponsor
- Sun Yat-sen University
- Start
- Jan 1, 2014
- Primary completion
- Dec 31, 2021
- Results posted
- No
- Registry record
- NCT01996098 · updated Sep 5, 2024
Publications
linked from the registry- Li N, Ou W, Cheng C, You J, Yang L, Chen FX, Liang Y, Yang Z, Wang BX, Chang ZH, Lin YB, Yang W, Xu F, Ding G, Chen XS, Hu R, Li S, Jiang H, Hu XX, Long H, Wang SY. Adjuvant icotinib for resected EGFR-mutated stage II-IIIA non-small-cell lung cancer (ICTAN, GASTO1002): a randomized comparison study. Signal Transduct Target Ther. 2025 Aug 28;10(1):273. doi: 10.1038/s41392-025-02358-w. PubMed 40866342